Lilly Doubles Down on Insilico’s AI Medicines, Bets Up to $2.75B

The Insilico Medicine agreement plays into Eli Lilly’s recent AI push, anchored by a partnership last year with NVIDIA to build a supercomputer to optimize drug discovery and shorten the development timeline.